Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014;8(4):294-307.
doi: 10.4161/19336918.2014.970026.

The role of proteases in regulating Eph/ephrin signaling

Affiliations
Review

The role of proteases in regulating Eph/ephrin signaling

Lakmali Atapattu et al. Cell Adh Migr. 2014.

Abstract

Proteases regulate a myriad of cell functions, both in normal and disease states. In addition to protein turnover, they regulate a range of signaling processes, including those mediated by Eph receptors and their ephrin ligands. A variety of proteases is reported to directly cleave Ephs and/or ephrins under different conditions, to promote receptor and/or ligand shedding, and regulate receptor/ligand internalisation and signaling. They also cleave other adhesion proteins in response to Eph-ephrin interactions, to indirectly facilitate Eph-mediated functions. Proteases thus contribute to Eph/ephrin mediated changes in cell-cell and cell-matrix interactions, in cell morphology and in cell migration and invasion, in a manner which appears to be tightly regulated by, and co-ordinated with, Eph signaling. This review summarizes the current literature describing the function and regulation of protease activities during Eph/ephrin-mediated cell signaling.

Keywords: AD, Alzheimer's disease; ADAM, a disintegrin and metalloprotease; APP, Amyloid precursor protein; Arf1, ADP rybosylation factor 1; BACE, β-site APP cleaving enzyme; CAM, cell adhesion molecules; CTF, cytoplasmic fragment; CNC, cranial neural crest; ECM,; ADAM; Eph receptor tyrosine kinase; MMP; ephrin signaling; protease; γ-secretase.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
An illustration of ADAM domain structure. ADAMs consist of a prodomain (pro), metalloprotease domain (MP), disintegrin domain (D), cysteine-rich domain (C), EGF-like domain (except for ADAM10 and 17), a transmembrane domain and a cytoplasmic domain.
Figure 2.
Figure 2.
Proposed mechanisms of Eph/ephrin induced ADAM shedding. (A) Prior to Eph/ephrin interaction: Eph is in an inactive conformation, via interactions between the juxtamembrane and kinase domains; ADAM10 is poorly associated. (B) When Eph/ephrin interaction occurs between adjacent cells, the Eph/ephrin complex provide a new interface recognized by a substrate binding pocket in the C domain of ADAM10, positioning the protease domain to cleave ephrin from the opposing cell. Eph activation results in release of the inactive conformation and elongation of the EphA3 cytoplasmic domain, moving the kinase domain away from the plasma membrane, and facilitating ADAM10 association and ephrin cleavage. (C) Conformation changes in the ADAM C domain are proposed to occur via protein disulfide isomerase (PDI) activity, switching disufide bonds at a conserved CxxC motif. Upon activation of RTK receptors, reactive oxygen species (ROS) are produced by NOXs (NADPH-oxidases), which in turn inhibit PDI to favor an ‘active’ ADAM conformation, able to bind the Eph/ephrin complex, cleave ephrin and enable cell-cell retraction.
Figure 3.
Figure 3.
MMPs in Eph and/or ephrin shedding. (A) Ephrin-B1 ectodomain cleavage by MMP8, which is enhanced upon interaction with the EphB2 receptor. Stimulation of ephrin-B1 by EphB2 activates the Arf1 GTPase, a critical regulator of membrane trafficking, most likely increasing the exocytosis of MMP8. The ephrin-B1 C-terminus also activates RhoA by binding to the adapter protein Dishevelled (Dsh), facilitating cell-cell repulsion and invasion. (B) Ephrin-B1-induced EphB2 receptor activation and its cleavage by MMP 2/9 cause RhoA activity via recruitment and subsequent activation of FAK, regulating growth cone withdrawal and collapse. (C) Clusters of overexpressed EphA2 recruit MT1-MMP via its non-catalytic domains, mediating cleavage of EphA2 in cis at the fibronectin repeat type-III domain, stimulated by binding to ephrin-A1, and activating Src/Rho-mediated invasion.
Figure 4.
Figure 4.
Regulated intramembrane proteolysis of Ephs/ephrins. (A) EphB/ephrin-B interaction can lead to sequential ectodomain and γ-secretase-mediated intramembrane proteolysis of both ligand and receptor in interacting cells. EphB2 bound ephrin-B2 ectodomain is cleaved by metalloprotease activity, generating a membrane bound cytoplasmic fragment (ephrin-B2-CTF1) which is further processed by γ-secretase, yielding a soluble cytoplasmic fragment (ephrin-B2-CTF2) (top cell). Inside the cell, ephrin-B2-CTF promotes tyrosine dephosphorylation of (PAG/Cbp), and relieves Csk-inhibition of Src kinases, which in turn facilitates tyrosine phosphorylation of ephrin-B2. Ligand-binding to EphB2 also promotes receptor ectodomain cleavage, endocytosis, and γ-secretase cleavage, to produce soluble Eph cytoplasmic domain (bottom cell). This regulated intramembrane proteolysis in both cells contributes to cytoskeletal regulation, migration, proliferation and survival. (B) EphA/B receptor ectodomain shedding also occurs in the apparent absence of ligand, via MMP/ADAM activity, stimulated by NMDA receptor signaling or calcim influx. The plasma membrane bound Eph cytoplasmic fragment (Eph-CTF) then undergoes γ-secretase cleavage. Both ligand-independent and -dependent EphB pathways may regulate NMDA receptor signaling and synaptic plasticity. In addition, calcium-stimulated EphA4 shedding at synapses promotes dendritic spine formation via Rac signaling.

Similar articles

Cited by

References

    1. Serim S, Haedke U, Verhelst SHL. Activity-based probes for the study of proteases: recent advances and developments. ChemMedChem 2012; 7:1146-59; PMID:22431376; http://dx.doi.org/10.1002/cmdc.201200057 - DOI - PubMed
    1. Drag M, Salvesen GS. Emerging principles in protease-based drug discovery. Nat Rev Drug Discov 2010; 9:690-701; PMID:20811381; http://dx.doi.org/10.1038/nrd3053 - DOI - PMC - PubMed
    1. Turk B. Targeting proteases: successes, failures and future prospects. Nat Rev Drug Dis 2006; 5:785-99; PMID:16955069; http://dx.doi.org/10.1038/nrd2092 - DOI - PubMed
    1. Lopez-Otin C, Bond JS. Proteases: multifunctional enzymes in life and disease. J Biol Chem 2008; 283:30433-7; PMID:18650443; http://dx.doi.org/10.1074/jbc.R800035200 - DOI - PMC - PubMed
    1. Overall CM, Blobel CP. In search of partners: linking extracellular proteases to substrates. Nat Rev Mol Cell Biol 2007; 8:245-57; PMID:17299501; http://dx.doi.org/10.1038/nrm2120 - DOI - PubMed